You can buy or sell Grifols and other stocks, options, ETFs, and crypto commission-free!
Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. Read More The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.
52 Week High
52 Week Low
Advertising and Marketing
PR NewswireApr 30
Grifols Announces PharmacyKeeper Bidirectional Integration with Epic
BARCELONA, Spain, April 30, 2019 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P,NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of technologies and services for hospitals, clinics and compounding centers, announced today that its PharmacyKeeper Verification IV Workflow Management system now supports bidirectional integration with Epic.
Yahoo FinanceApr 29
Grifols Announces the Opening of its new Plasma Donor Center in Hinesville, Georgia
Investing $1.6 million into local community; set to employ over 40 people from the local area HINESVILLE, Ga., April 29, 2019 /PRNewswire/ -- Grifols is pleased to announce the opening of a new Biotest plasma donor center located at 108 West Hendry Street, Hinesville, Georgia. The 11,000 square foot state-of-the-art facility officially opened its doors for business on April 29, 2019. Ileana Carlisle, Biotest President, said "We look forward to being an active member of the Hinesville community. Th...
$0.30 per share
Expected May 30, Pre-Market